FDA Warning Letter due to Non-Compliance with Specifications
Recommendation
Tuesday, 4 February 2025 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
This FDA Warning Letter issued to Indian drug manufacturer Kim Chemicals Private Ltd. on 16 October, 2017, is based on an FDA inspection conducted in July 2017.
The FDA criticised that not all drug products and the active substances they contained had been tested for compliance with their specifications before release. Some batches were distributed to the USA even though the active ingredient content was out of specification (OOS). They had simply copied values from old certificates of analysis to the new batches' certificates of analysis.
In quality control, there were no written procedures in the form of SOPs for a number of critical processes. This included requirements for:
- Complaint handling
- Recalls
- Investigation of OOS results
- Deviation investigation
- Returns
- Stability
Furthermore, no data could be supplied to verify the values listed in the analysis certificates.
The performed tests had been noted down in a piece of paper and then transferred to the certificate of analysis, while the piece of paper was simply discarded. Also, there were no records on how the calculation had been performed.
The FDA therefore concluded that the company's quality management system is not fit to verify the accuracy and integrity of data.
Source: FDA Warning Letter to Kim Chemicals Private Ltd.
Related GMP News
16.10.2024US FDA Warning Letter: Lab Data Integrity issues
16.10.2024FDA Warning Letter: Component Testing, Validation, and Stability
16.10.2024EDQM publishes New Chapter "Quality of Data" for Comments
16.10.2024USP Chapter <621> Chromatography: Notice of Intent to Revise
15.10.2024Pharmeuropa Text for Comment: HPTLC for Herbal Products
09.10.2024WHO Biowaiver Project Cycle VII (2025) and Results from Cycle VI (2024)